Maxim Group Reaffirms Their Buy Rating on OncoSec Medical

By Jason Carr

In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on OncoSec Medical (NASDAQ: ONCS), with a price target of $5. The company’s shares opened today at $1.80.

McCarthy wrote:

“OncoSec provided an update on TAVO (DNA-based IL-12) clinical programs at AACR (American Association of Cancer Research) including both melanoma and triple negative breast cancer (TNBC).”

According to, McCarthy is a 3-star analyst with an average return of 2.6% and a 40.4% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Actinium Pharmaceuticals.

OncoSec Medical has an analyst consensus of Moderate Buy, with a price target consensus of $5.50.

Based on OncoSec Medical’s latest earnings report for the quarter ending January 31, the company posted quarterly revenue of $0 and GAAP net loss of $10.74 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $5.39 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

OncoSec Medical, Inc. engages in the design and commercialize medical products for the treatment of cancer. It involves in the discovery and development of novel immunotherapeutic products to improve treatment options for patients and physicians, which intends to treat oncology indications. The company was founded by Avtar S. Dhillon, Punit S.